XML 33 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 32,928 $ 120,841
Receivables from collaboration 1,679 50,436
Inventory 23,402 9,670
Prepaid expenses and other current assets 13,227 20,206
Total current assets 71,236 201,153
Property and equipment - net 191,408 192,127
Deferred product costs from collaboration 13,539  
Other assets 1,831 1,159
Total assets 278,014 394,439
Current liabilities:    
Accounts payable 4,444 7,394
Accrued expenses and other current liabilities 14,081 26,206
Facility financing obligation 74,163 72,995
Senior convertible notes-current   99,355
Deferred product sales from collaboration 17,474 436
Deferred payments from collaboration 157,145 196,967
Total current liabilities 267,307 403,353
Note payable to principal stockholder 49,521 49,521
Sanofi loan facility and loss share obligation 43,653 3,034
Senior convertible notes-long term 27,607  
Other liabilities 14,495 12,301
Total liabilities $ 402,583 $ 468,209
Commitments and contingencies
Stockholders' deficit:    
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2015 and December 31, 2014
Common stock, $0.01 par value - 550,000,000 shares authorized at September 30, 2015 and December 31, 2014; 418,263,814 and 406,059,089 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively $ 4,182 $ 4,061
Additional paid-in capital 2,457,482 2,416,967
Accumulated other comprehensive loss (19) (14)
Accumulated deficit (2,586,214) (2,494,784)
Total stockholders' deficit (124,569) (73,770)
Total $ 278,014 $ 394,439